
I. RECORDS REQUESTED
For the 24 food contact substance notifications (FCNs) listed below and posted on its website at https://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=fcn, EDF is requesting the original notice submitted by the company and any correspondence between FDA and the company. We are also requesting any toxicology, chemistry or environmental assessment reports prepared by FDA in its evaluation of the notices.

<table>
<thead>
<tr>
<th>FCN No.</th>
<th>Food Contact Substance</th>
<th>Manufacturer/Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>195</td>
<td>Diphosphoric acid, polymers with ethoxylated reduced Me esters of reduced polymerized oxidized tetrafluoroethylene. This substance is also known as: phosphate esters of ethoxylated perfluoroether, prepared by reaction of ethoxylated perfluoroether diol (CAS Reg. No. 162492-15-1) with phosphorous pentoxide (CAS Reg. No. 1314-56-3) or pyrophosphoric acid (CAS Reg. No. 2466-09-3).</td>
<td>Solvay Specialty Polymers USA, LLC</td>
</tr>
<tr>
<td>314</td>
<td>2-Propen-1-ol, reaction products with pentafluorodiethanetetrafluoroethylene telomer, dehydroiodinated, reaction products with epichlorohydrin and triethylenetetramine (CAS Reg. No. 464178-90-3).</td>
<td>Solenis LLC</td>
</tr>
<tr>
<td>416</td>
<td>Diphosphoric acid, polymers with ethoxylated reduced Me esters of reduced polymerized oxidized tetrafluoroethylene. This substance is also known as: phosphate esters of ethoxylated perfluoroether, prepared by reaction of ethoxylated perfluoroether diol (CAS Reg. No. 162492-15-1) with phosphorous pentoxide (CAS Reg. No. 1314-56-3) or pyrophosphoric acid (CAS Reg. No. 2466-09-3).</td>
<td>Solvay Specialty Polymers USA, LLC</td>
</tr>
<tr>
<td>487</td>
<td>2-propen-1-ol, reaction products with pentafluorodiethanetetrafluoroethylene telomer, dehydroiodinated, reaction products with epichlorohydrin and triethylenetetramine (CAS Reg. No. 464178-90-3).</td>
<td>Solenis LLC</td>
</tr>
<tr>
<td>510</td>
<td>Copolymer of 1,1-difluoroethylene, hexafluoropropene, tetrafluoroethylene, and a halogenated alkene, optionally cured with triallyl isocyanurate and 2,5-dimethyl-2,5-di(tetrafluoroxy)hexane.</td>
<td>The Chemours Company FC, LLC</td>
</tr>
</tbody>
</table>
511 Copolymer of 1,1-difluoroethylene, tetrafluoroethylene, trifluoroethyl vinyl ether and a halogenated alkene, optionally cured with triallyl isocyanurate and 2,5-dimethyl-2,5-di(tert-butylperoxy)hexane.

The Chemours Company FC, LLC

518 2-propen-1-ol, reaction products with perfluorovinylidene-tetrafluoroethylene telomer, dehydroiodinated, reaction products with epichlorohydin and triethylentetramine (CAS Reg. No 464178-90-3).

Solenis LLC


Solvay Specialty Polymers Italy S.p.A.

539 A copolymer of 4-bromo-3,3,4,4-tetrafluoro-1-butene, ethylene, tetrafluoroethylene and trifluoromethyl trifluoro vinyl ether ether optionally cured with triallyl isocyanurate and 2,5-dimethyl-2,5-di(tert-butylperoxy)hexane. (CAS Reg. No. 105656-63-1)

The Chemours Company FC, LLC

542 2-propen-1-ol, reaction products with 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluoro-6-iodohexane, dehydroiodinated, reaction products with epichlorohydin and triethylentetramine (CAS Reg. No. 464178-94-7).

Solenis LLC

598 A copolymer of propylene (CAS Reg. No. 115-07-1), tetrafluoroethylene (CAS Reg. No. 116-14-3), and 3,3,3-trifluoropropene (CAS Reg. No. 677-21-4) cured with a salt of a quaternary ammonium compound and phenol, 4,4'-(2,2,2-trifluoro-1-(trifluoromethyl)ethylidene)bis-.

The Chemours Company FC, LLC

604 Copolymer of perfluorohexylethyl methacrylate, 2-N,N-diethylaminoethyl methacrylate, 2-hydroxyethyl methacrylate, and 2,2'-ethylenedioxydiethyl dimethacrylate, acetic acid salt

Asahi Glass Company, Ltd. (Manufacturer) AGC Chemicals Americas, Inc.

746 2-propenoic acid, 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-octyl ester, polymer with α-(1-oxo-2-propen-1-yl)-ω-hydroxypoly(oxy-1,2-ethanediyl).

Daikin America, Inc.

827 2-propenoic acid, 2-hydroxyethyl ester, polymer with α-(1-oxo-2-propen-1-yl)-ω-hydroxypoly(oxy-1,2-ethanediyl), α-(1-oxo-2-propen-1-yl)-ω-[(1-oxo-2-propen-1-yl)oxy]poly(oxy-1,2-ethanediyl) and 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoroctyl 2-propenoate

Daikin America, Inc.

885 2-propenoic acid, 2-methyl-, polymer with 2-(diethylamino)ethyl 2-methyl-2-propenoate, 2-propenoic acid and 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoroctyl 2-methyl-2-propenoate, acetate (CAS Reg. No. 1071022-26-8)

The Chemours Company FC, LLC

888 2-propenoic acid, 2-hydroxyethyl ester, polymer with α-(1-oxo-2-propen-1-yl)-ω-hydroxypoly(oxy-1,2-ethanediyl), α-(1-oxo-2-propen-1-yl)-ω-[(1-oxo-2-propen-1-yl)oxy]poly(oxy-1,2-ethanediyl) and 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoroctyl 2-propenoate

Daikin America, Inc.

933 2-propenoic acid, 2-methyl-, polymer with 2-hydroxyethyl 2-methyl-2-propenoate, α-(1-oxo-2-propen-1-yl)-ω-hydroxypoly(oxy-1,2-ethanediyl) and 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoroctyl 2-propenoate, sodium salt (CAS Reg. No. 1158951-86-0).

Daikin America, Inc.

940 Hexane, 1,6-diisocyanatooctafluorodecane, homopolymer, 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-1-octanol-blocked (CAS Reg. No. 357624-15-8).

The Chemours Company FC, LLC


The Chemours Company FC, LLC
II. A FEE WAIVER IS APPROPRIATE
Pursuant to 5 U.S.C. § 552(a)(4)(A)(iii) and 21 C.F.R. § 20.46, EDF requests that FDA waive all fees associated with responding to this request because EDF seeks this information in the public interest and will not benefit commercially from this request.

FOIA provides that fees shall be reduced “if disclosure of the information is in the public interest because it is likely to contribute significantly to public understanding of the operations or activities of the government and is not primarily in the commercial interest of the requester.” 5 U.S.C. § 552(a)(4)(A)(iii). FDA’s FOIA regulations contain a nearly identical requirement and identify six factors to assess whether a requester is entitled to a waiver of fees under FOIA. 21 C.F.R. § 20.46.

FOIA carries a presumption of disclosure, and the fee waiver was designed specifically to allow nonprofit, public-interest groups, such as EDF, access to government documents without the payment of fees. The courts have stated that the statute “is to be liberally construed in favor of waivers for noncommercial requesters.” See Judicial Watch v. Rossotti, 326 F.3d 1309, 1312 (D.C. Cir. 2003). As explained below, EDF meets the criteria for a fee waiver established in FOIA and outlined in FDA’s implementing regulations.

A. Disclosure of this information is in the public interest because it will likely contribute significantly to public understanding of the operations or activities of the government.

EDF qualifies for a fee waiver because the requested information will contribute significantly to public understanding of the operations or activities of the federal government. See 21 C.F.R. § 20.46(b). EDF possesses the ability to disseminate the information to the general public, and, in fact, such dissemination is routine to their operations.
EDF is active in informing their constituencies about perchlorate exposure and are well-positioned to enhance the public’s understanding of potential exposures through food by analyzing and disseminating the requested information to members and the general public.

1. The Subject Matter of the Requested Documents Pertain to Operations or Activities of the Federal Government

Moreover, we are requesting the records with reasonable specificity. See Rossotti, 326 F.3d at 1313 (D.C. Cir. 2003) (quoting Larson v. Cent. Intelligence Agency, 843 F.2d 1481, 1483 (D.C. Cir. 1988)) (noting that to satisfy the first prong of a fee waiver request, government operations or activities must only be identified with “‘reasonable specificity’—all that FOIA requires”). Here, EDF requests a reasonably specified set of records.

2. The Disclosure Would Likely Reveal Meaningful Information about Government Operations or Activities that is not Already Public Knowledge
Under the second factor used to consider fee waivers, FDA must consider “[w]hether disclosure of the records would reveal any meaningful information about Government operations or activities that is not already public knowledge.” 21 C.F.R. § 20.46(b)(2). Disclosure of the requested records is likely to reveal “meaningful information” about government operations or activities by allowing the public to see which products have been found to contain perchlorate and the product manufacturers. This information is meaningful because there is wide public concern about exposure to perchlorate given recent attention to the hazards of perchlorate in drinking water. Therefore, the foregoing request for documents meets the second factor for a fee waiver by seeking “meaningful information” that is not already public knowledge.

3. The Disclosure Will Advance the Understanding of the General Public as Distinguished from a Narrow Segment of Interested Persons
Under the third factor, FDA regulations state that it “may consider whether the requester has such knowledge or expertise as may be necessary to understand the information” and “whether the requester's intended use of the information would be likely to disseminate the information to the public.” 21 C.F.R. § 20.46(b)(3). In determining whether the disclosure of requested information will advance the understanding of the general public, a guiding test is whether the disclosed documents will reach “a reasonably broad audience of persons interested in the subject.” Carney v. U.S. Dep’t of Justice, 19 F.3d 807, 815 (2d Cir. 1994). EDF uses a variety of platforms to disseminate information to the public. For example, EDF has the capacity to write a report analyzing and summarizing information obtained through the FOIA request, and publicize the report to its two million members and activists through
its blog and other publications. EDF’s use of a variety of platforms ensures that the requested information will reach a “reasonably broad” audience of people.

4. The Contribution to the General Public Will Likely Be Significant
   As described above, EDF communicates with supporters, members and the general public through a variety of means. EDF plans to disseminate the pertinent information contained in the requested records to affected communities and stakeholders across the country. This type of dissemination has been held sufficient to satisfy this prong of the fee waiver determination. *See Judicial Watch, Inc. v. Gen. Servs. Admin.*, CIV.A. 98-2223 (RMU), 2000 WL 35538030, at *9 (D.D.C. Sept. 25, 2000) (holding that an organization satisfied FOIA’s requirement that information be disseminated to a reasonably broad segment of the public where the organization had an established history of disseminating information and proposed to post disclosed information for public review on its website); *see also D.C. Technical Assistance Org., Inc. v. U.S. Dep’t of Hous. & Urban Dev.*, 85 F. Supp. 2d 46, 49 (D.D.C. 2000) (“In this Information Age, technology has made it possible for almost anyone to fulfill [FOIA’s dissemination requirement].”); *see also Or. Natural Desert Ass’n v. U.S. Dep’t of Interior*, 24 F. Supp. 2d 1088, 1095-96 (D. Or. 1998) (relying on *Friends of the Coast Fork v. U.S. Dep’t of the Interior*, 110 F.3d 53, 55-56 (9th Cir. 1997)) (finding that the organization established a prima facie case that “contribution to public understanding” was significant where organization sought a fee waiver request for monitoring data and gave a “lengthy articulation of its reasons for requesting the information,” explained “what it would do with that information,” “how [it] would disseminate” the information, and “to whom”).

Furthermore, information about the brands of food that have been identified as containing unusually high levels of perchlorate in the TDS sampling is not readily available to the public. Disclosure and dissemination of this information would enhance the public’s ability to make fully informed purchases of food. The current absence of the FDA’s data in the public domain, coupled with EDF’s ability and intent to disseminate the records upon disclosure, is sufficient to satisfy the significance prong of a fee waiver request. *See Fed. CURE v. Lappin*, 602 F. Supp. 2d 197, 205–06 (D.D.C. 2009) (finding that, even in the absence of a “specific plan for interpreting [] information before disseminat[ion],” the public’s understanding will be significantly enhanced by disseminating information otherwise not in the public domain).

B. Obtaining the Information Is of No Commercial Interest to EDF
   The fifth and sixth factors FDA must consider relate to the possible existence and magnitude of a commercial interest in disclosure. *See 21 C.F.R. § 20.46(c).* Two questions must be addressed when determining whether the information requested is “primarily in the commercial interest of the requester.” 5 U.S.C. § 552(a)(4)(A)(iii). The first question is whether the requester has a commercial interest that would be furthered by the requested disclosure. Here, as a 501(c)(3) nonprofit entity, EDF has no commercial, trade, or profit interest in the material requested. EDF will not be paid for or receive other commercial benefits from the publication or dissemination of the material requested. The requested material will be disseminated solely for the purpose of informing and educating the public and will not be used for commercial use or gain.

The final factor hinges on the primary interest in the disclosure. FDA must assess whether any commercial interest “outweighs the advancement of the public interest.” *21 C.F.R. § 20.46(c).* There is great public interest in the release of the materials sought because they will allow for a more thorough understanding of how parents can protect their children from perchlorate. This information will contribute to the numerous other public interest organizations looking at perchlorate exposure through various pathways throughout the country. The disclosure of the
requested information is therefore “not primarily in the commercial interest of” EDF, and a fee waiver is appropriate. 5 U.S.C. § 552(a)(4)(A)(iii).

Under these circumstances, EDF fully satisfies the criteria for a fee waiver.

III. CONCLUSION
Pursuant to FOIA and FDA’s FOIA regulations, the agency has 20 working days from the date of its receipt of this request to decide whether to grant the request, and it must notify the requester of the decision. See 5 U.S.C. § 551(a)(6)(A)(i); 21 C.F.R. § 20.41(b). Please produce the requested records by emailing or mailing them to the address listed below. Please also produce the records on a rolling basis; at no point should FDA’s search for, or deliberations concerning, certain records delay the production of others that FDA has already retrieved and elected to produce.

If you have any questions about the records we are seeking, you can contact me at the information below. We also welcome the opportunity to clarify our request with FDA’s FOIA Officer(s) via phone.

If for some reason the fee waiver is denied, please contact me before incurring any costs related to this request. If the fee waiver is not granted and costs are incurred prior to approval by EDF, it will not be responsible for those costs.

Thank you in advance for your prompt reply.

Sincerely,

Tom Neltner

Tom Neltner, Chemicals Policy Director
Environmental Defense Fund
1875 Connecticut Ave. NW, Suite 600
Washington, DC 20009
tneltner@edf.org
202-572-3263